Completed PHASE4 INTERVENTIONAL 2-arm NCT02147691

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

Sponsor: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Interventions Azelaic acid 15% Brimonidine 0.33%

Updated 7 times since 2017 Last updated: Aug 28, 2015 Started: May 31, 2014 Primary completion: Jan 31, 2015 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acne Rosacea and is currently completed. Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Derm Research, PLLC

Data source: Derm Research, PLLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Louisville, United States